In December 2012, CRI and the nonprofit Stand Up To Cancer (SU2C), along with SU2C’s scientific partner, the American Association for Cancer Research, announced a $10 million grant to support a Cancer Immunology Translational Research Dream Team. The award allows the Dream Team to focus on developing cancer treatments based on immunological checkpoint blockade combined with adoptive T cell transfer, two highly promising approaches to cancer immunotherapy.

*Immunotherapy results may vary from patient to patient.